Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Anbio Biotechnology Class A Ordinary Shares (NNNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: NNNN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 266.58% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 5.18 - 37.08 | Updated Date 05/15/2025 |
52 Weeks Range 5.18 - 37.08 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Anbio Biotechnology Class A Ordinary Shares
Company Overview
History and Background
Anbio Biotechnology is a biopharmaceutical company focused on developing and commercializing innovative diagnostic and therapeutic solutions. The company has been involved in research and development of novel technologies for infectious diseases and cancer diagnostics. Significant milestones include the development and regulatory approval of certain diagnostic kits in specific markets.
Core Business Areas
- Infectious Disease Diagnostics: Development and commercialization of rapid diagnostic tests for various infectious diseases, aiming for quick and accurate detection.
- Oncology Diagnostics: Focus on developing advanced diagnostic tools and biomarkers for early cancer detection, prognosis, and personalized treatment selection.
- Therapeutic Development: Exploration and development of potential therapeutic candidates, often targeting diseases with unmet medical needs.
Leadership and Structure
Information regarding the specific leadership team and detailed organizational structure for Anbio Biotechnology Class A Ordinary Shares is not readily available in public domain for this specific share class without further in-depth research into company filings and official reports.
Top Products and Market Share
Key Offerings
- Product Name 1: Rapid diagnostic kits for infectious diseases. These kits aim to provide results within minutes, facilitating faster clinical decisions. Market share data is not publicly disclosed. Competitors include major diagnostic companies like Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers.
- Product Name 2: Oncology biomarkers and diagnostic assays. These products are designed to aid in cancer diagnosis and treatment selection. Specific revenue figures and market share are not publicly detailed. Competitors include companies like Thermo Fisher Scientific, Illumina, and Guardant Health.
Market Dynamics
Industry Overview
The biotechnology and diagnostics industry is characterized by rapid innovation, significant R&D investment, and a growing demand for personalized medicine and advanced disease detection. The global diagnostics market is substantial and growing, driven by an aging population, increasing prevalence of chronic diseases, and advancements in molecular diagnostics.
Positioning
Anbio Biotechnology aims to position itself as an innovator in specific niches within diagnostics and therapeutics, focusing on unmet medical needs. Its competitive advantages may lie in proprietary technologies and a targeted approach to disease areas.
Total Addressable Market (TAM)
The TAM for the global diagnostics market is in the hundreds of billions of dollars, with diagnostics for infectious diseases and oncology representing significant segments. Anbio Biotechnology, as a smaller player, would target specific sub-segments within this TAM. Its positioning depends on the success of its specific product pipelines and market penetration strategies.
Upturn SWOT Analysis
Strengths
- Proprietary diagnostic technologies.
- Focus on high-demand areas like infectious diseases and oncology.
- Potential for innovative therapeutic candidates.
Weaknesses
- Limited brand recognition compared to established players.
- Dependence on successful R&D outcomes and regulatory approvals.
- Potential for high R&D costs and long development cycles.
Opportunities
- Increasing global demand for rapid diagnostics.
- Growth in personalized medicine and targeted cancer therapies.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into emerging markets.
Threats
- Intense competition from established biotechnology and pharmaceutical firms.
- Stringent regulatory hurdles and approval processes.
- Rapid technological advancements that could render existing products obsolete.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Roche Holding AG (RHHBY)
- Thermo Fisher Scientific Inc. (TMO)
- Siemens AG (SIEGY)
Competitive Landscape
Anbio Biotechnology faces intense competition from larger, well-established companies with significant resources for R&D, marketing, and sales. Its advantages would lie in niche product development and speed to market for specialized diagnostics. Disadvantages include scale, financial resources, and market access compared to incumbents.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends for Anbio Biotechnology Class A Ordinary Shares are not publicly detailed.
Future Projections: Future growth projections for Anbio Biotechnology Class A Ordinary Shares are not publicly available and would depend on the success of its R&D pipeline and market penetration strategies.
Recent Initiatives: Information on recent strategic initiatives undertaken by Anbio Biotechnology Class A Ordinary Shares is not readily accessible.
Summary
Anbio Biotechnology operates in dynamic diagnostic and therapeutic markets with potential for innovation. While its focus on critical areas like infectious diseases and oncology is promising, the company faces significant hurdles due to intense competition and regulatory complexities. Its success hinges on the effective execution of its R&D pipeline and strategic market entry, as detailed financial and growth data are not readily available for a comprehensive assessment.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry analysis reports (e.g., market research firms).
- Publicly available company information (where accessible).
- General knowledge of the biotechnology and diagnostics sectors.
Disclaimers:
The information provided is based on publicly available data and general industry knowledge. Specific financial performance, detailed product sales, market share, and strategic initiatives for Anbio Biotechnology Class A Ordinary Shares may not be fully accessible or up-to-date. This analysis is for informational purposes only and should not be considered financial advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anbio Biotechnology Class A Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-02-19 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 27 | Website https://www.anbio.com |
Full time employees 27 | Website https://www.anbio.com | ||
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.